This work reports a new method for the synthesis of water-soluble Au₉nanoclusters and a strikingly visible temperature- and pH-dependent isomerization.

Bio-orthogonal chemistry provides a powerful tool for drug delivery systems due to its ability to generate therapeutic agents in situ, minimizing off-target effects. Bio-orthogonal transition metal catalysts (TMCs) with stimuli-responsive properties offer possibilities for controllable catalysis due to their spatial-, temporal-, and dosage-controllable properties. In this paper, we fabricated a stimuli-responsive bio-orthogonal catalysis system based on an enhanced green fluorescent protein (EGFP)–nanozyme (NZ) complex (EGFP-NZ). Regulation of the catalytic properties of the EGFP-NZ complex was directly achieved by modulating the ionic strength of the solution. The dielectric screening introduced by salt ions allows the dissociation of the EGFP-NZ complex, increasing the access of substrate to the active site of the NZs and concomitantly increasing nanozyme activity. The change in catalytic rate of the NZ/EGFP = 1:1 complex was positively correlated with salt concentration from 0 mM to 150 mM.

In this work we show that biological inactive gold nanoclusters (AuNCs) capped with D-maltose can be converted to antimicrobial AuI species by the addition of thiourea (TU). The antimicrobial activity mainly arises from the reaction of AuNCs with TU generating [Au(TU)2]Cl and small Au nanoclusters. Excess TU also maintains the oxidation state as AuI (vs. AuIII) which is key in maintaining activity. The AuNCs/TU combination was a powerful bactericidal agent against resistant bacteria, including multidrug-resistant (MDR) clinical isolates of Pseudomonas aeruginosa, and could eradicate S. epidermidis biofilm. It is unaffected by the efflux or bacterial outer membrane. The modes of action are multiple, including inhibition of thioredoxin reductase, CuI regulation interference and depletion of ATP. The formulation was 30-60 times less toxic on mammalian cells. This represents a new strategy enabling the antimicrobial activity of otherwise inactive AuNCs against the most difficult to treat MDR bacteria.